This study aims to collect clinical, biological and quality of life data from patients with a borderline or resectable pancreatic cancer. It will collect information from the date of diagnosis along the therapeutic care of the patients, and a 3-years follow-up after the end of the treatment. The database will be updated at each patient's visit. Biological samples will include: tumor, and plasma. Epidemiological data will also be collected, whereas Quality of life will be assessed by the EORTC standard. The objectives of this database are to identify new biomarkers (genomic, immunologic, and epidemiologic) and promote high quality standard research protocol.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
OTHER
Masking
NONE
Enrollment
290
blood and tumor tissue samples
Centre Hospitalier Régional Universitaire de Besançon
Besançon, France
Centre Georges François Leclerc
Dijon, France
Centre Hospitalier Universitaire de Dijon
Dijon, France
Centre Hospitalier Universitaire de Nancy
Nancy, France
Institut de cancérologie de Lorraine
Nancy, France
Centre Hospitalier Universitaire Robert Debré
Reims, France
Centre Paul Strauss
Strasbourg, France
CHU de Strasbourg - Hautepierre
Strasbourg, France
disease-free survival according to the consensus DATECAN (Bonnetain F et al, European Journal of Cancer 2014)
DATECAN = Definition for the Assessment of Time-to-event Endpoints in CANcer trials
Time frame: date of first disease apparition [within 3 years after the enrollment of the last patient]
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.